Refractory Cholangiocarcinoma

MedGen UID:: 1672791
•Concept ID:: C4764050
•: Neoplastic Process

Definition

Cholangiocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVRefractory Cholangiocarcinoma

Abnormality of the liver
- Abnormality of the biliary system
  - Biliary tract abnormality
    - Abnormal biliary tract morphology
      - Biliary tract neoplasm
        Cholangiocarcinoma
        Refractory Cholangiocarcinoma
        Refractory Distal Bile Duct Adenocarcinoma
        Refractory Intrahepatic Cholangiocarcinoma

Professional guidelines

PubMed

New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option.

Dewald CLA, Becker LS, Meine TC, Maschke SK, Wacker FK, Saborowski A, Vogel A, Hinrichs JB
Clin Exp Metastasis 2023 Feb;40(1):95-104. Epub 2022 Nov 22 doi: 10.1007/s10585-022-10193-4. PMID: 36417096 Free PMC Article

See all (1)

Recent clinical studies

Etiology

New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option.

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX
Lancet Oncol 2020 Jun;21(6):796-807. Epub 2020 May 13 doi: 10.1016/S1470-2045(20)30157-1. PMID: 32416072 Free PMC Article

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T
J Clin Oncol 2018 Jan 20;36(3):276-282. Epub 2017 Nov 28 doi: 10.1200/JCO.2017.75.5009. PMID: 29182496 Free PMC Article

See all (3)

Diagnosis

New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option.

See all (1)

Therapy

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.

Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM
Oncologist 2024 Apr 4;29(4):e514-e525. doi: 10.1093/oncolo/oyad338. PMID: 38297981 Free PMC Article

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.

Casak SJ, Pradhan S, Fashoyin-Aje LA, Ren Y, Shen YL, Xu Y, Chow ECY, Xiong Y, Zirklelbach JF, Liu J, Charlab R, Pierce WF, Fesenko N, Beaver JA, Pazdur R, Kluetz PG, Lemery SJ
Clin Cancer Res 2022 Jul 1;28(13):2733-2737. doi: 10.1158/1078-0432.CCR-21-4462. PMID: 35259259 Free PMC Article

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.

Gbolahan O, Hashemi-Sadraei N, O'Neil B
J Natl Compr Canc Netw 2019 Jun 1;17(6):644-648. doi: 10.6004/jnccn.2019.7304. PMID: 31200359

A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.

Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX
Cancer 2017 Jun 1;123(11):1979-1988. Epub 2017 Feb 13 doi: 10.1002/cncr.30571. PMID: 28192597 Free PMC Article

See all (6)